Clinical Trial Update: TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions [Phase 1]

View source ↗

Summary

Phase 1 trial comparing 800 mg prototype darunavir tablet bioavailability to the 400 mg commercial tablet, with low-dose ritonavir, under fasted and fed conditi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Darunavir (darunavir)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: HIV Infections | Phase 1 | Status: COMPLETED